This article collection highlights the rise of #MASH and alcohol-related liver disease, their synergistic pathobiology now termed #metALD, and new mechanistic insights into these diseases published in CMGH ⬇️
💚https://ow.ly/Cfn051010MG
#LiverAwarenessMonth #LiverHealth #liverdisease
💚https://ow.ly/Cfn051010MG
#LiverAwarenessMonth #LiverHealth #liverdisease
October 26, 2026 at 3:35 PM
This article collection highlights the rise of #MASH and alcohol-related liver disease, their synergistic pathobiology now termed #metALD, and new mechanistic insights into these diseases published in CMGH ⬇️
💚https://ow.ly/Cfn051010MG
#LiverAwarenessMonth #LiverHealth #liverdisease
💚https://ow.ly/Cfn051010MG
#LiverAwarenessMonth #LiverHealth #liverdisease
MetALD highlights why metabolic risk and alcohol exposure should be assessed together—not in isolation.
The overlap may accelerate fibrosis and worsen liver outcomes, making integrated risk assessment increasingly important.
#Hepatology #MetALD #MASLD #LiverDisease #ClinicalEvidence #MedSky
The overlap may accelerate fibrosis and worsen liver outcomes, making integrated risk assessment increasingly important.
#Hepatology #MetALD #MASLD #LiverDisease #ClinicalEvidence #MedSky
October 23, 2026 at 3:58 AM
MetALD highlights why metabolic risk and alcohol exposure should be assessed together—not in isolation.
The overlap may accelerate fibrosis and worsen liver outcomes, making integrated risk assessment increasingly important.
#Hepatology #MetALD #MASLD #LiverDisease #ClinicalEvidence #MedSky
The overlap may accelerate fibrosis and worsen liver outcomes, making integrated risk assessment increasingly important.
#Hepatology #MetALD #MASLD #LiverDisease #ClinicalEvidence #MedSky
Proinflammatory Diets Linked to Higher MASLD, MetALD Mortality www.ajmc.com/view/proinfl...
Proinflammatory Diets Linked to Higher MASLD, MetALD Mortality | AJMC
Proinflammatory diets were tied to higher mortality in MASLD and MetALD, whereas antioxidant-rich diets tracked with better survival.
www.ajmc.com
October 19, 2026 at 2:46 PM
Proinflammatory Diets Linked to Higher MASLD, MetALD Mortality www.ajmc.com/view/proinfl...
🆕 #eGastroenterology
MASLD–MetALD–ALD: A dynamic continuum!
🔄 Disease categories can shift over time
🍷 Alcohol & metabolic risks interact
🔬 Objective assessment matters
🎯 Towards personalised care
📖 doi.org/10.1136/egas...
#LiverDisease #MASLD @lanlan-chen.bsky.social
MASLD–MetALD–ALD: A dynamic continuum!
🔄 Disease categories can shift over time
🍷 Alcohol & metabolic risks interact
🔬 Objective assessment matters
🎯 Towards personalised care
📖 doi.org/10.1136/egas...
#LiverDisease #MASLD @lanlan-chen.bsky.social
October 20, 2026 at 2:36 AM
🆕 #eGastroenterology
MASLD–MetALD–ALD: A dynamic continuum!
🔄 Disease categories can shift over time
🍷 Alcohol & metabolic risks interact
🔬 Objective assessment matters
🎯 Towards personalised care
📖 doi.org/10.1136/egas...
#LiverDisease #MASLD @lanlan-chen.bsky.social
MASLD–MetALD–ALD: A dynamic continuum!
🔄 Disease categories can shift over time
🍷 Alcohol & metabolic risks interact
🔬 Objective assessment matters
🎯 Towards personalised care
📖 doi.org/10.1136/egas...
#LiverDisease #MASLD @lanlan-chen.bsky.social
(Food Science & Nutrition).
Based on findings, improving dietary quality among patients with MetALD should be prioritized alongside counseling to reduce alcohol intake. Suggested dietary changes: whole grains, limiting fried foods & processed red meat, more vegetables, fruits, legumes, and berries.
Based on findings, improving dietary quality among patients with MetALD should be prioritized alongside counseling to reduce alcohol intake. Suggested dietary changes: whole grains, limiting fried foods & processed red meat, more vegetables, fruits, legumes, and berries.
October 19, 2026 at 2:52 PM
(Food Science & Nutrition).
Based on findings, improving dietary quality among patients with MetALD should be prioritized alongside counseling to reduce alcohol intake. Suggested dietary changes: whole grains, limiting fried foods & processed red meat, more vegetables, fruits, legumes, and berries.
Based on findings, improving dietary quality among patients with MetALD should be prioritized alongside counseling to reduce alcohol intake. Suggested dietary changes: whole grains, limiting fried foods & processed red meat, more vegetables, fruits, legumes, and berries.
Keep your education on-the-go with our Oct. 27 webinar discussing newly proposed definitions of #obesity and the genetic and metabolic factors in the pathogenesis of lean #MASLD. Hear from the experts on this timely discussion and register today https://bit.ly/3W5SXeQ.
#METALD #ALD
#METALD #ALD
October 15, 2026 at 5:18 PM
Keep your education on-the-go with our Oct. 27 webinar discussing newly proposed definitions of #obesity and the genetic and metabolic factors in the pathogenesis of lean #MASLD. Hear from the experts on this timely discussion and register today https://bit.ly/3W5SXeQ.
#METALD #ALD
#METALD #ALD
📢 New Review in #LiversMDPI
🧬 Stem et al. examine fructose–alcohol interactions in MetALD.
🩺 Pathways include mitochondrial dysfunction, lipid metabolism, and gut–liver axis disruption.
📖 Read More: www.mdpi.com/2673-4389/6/...
#MetALD #Fructose #Hepatotoxicity
🧬 Stem et al. examine fructose–alcohol interactions in MetALD.
🩺 Pathways include mitochondrial dysfunction, lipid metabolism, and gut–liver axis disruption.
📖 Read More: www.mdpi.com/2673-4389/6/...
#MetALD #Fructose #Hepatotoxicity
October 13, 2026 at 6:39 AM
📢 New Review in #LiversMDPI
🧬 Stem et al. examine fructose–alcohol interactions in MetALD.
🩺 Pathways include mitochondrial dysfunction, lipid metabolism, and gut–liver axis disruption.
📖 Read More: www.mdpi.com/2673-4389/6/...
#MetALD #Fructose #Hepatotoxicity
🧬 Stem et al. examine fructose–alcohol interactions in MetALD.
🩺 Pathways include mitochondrial dysfunction, lipid metabolism, and gut–liver axis disruption.
📖 Read More: www.mdpi.com/2673-4389/6/...
#MetALD #Fructose #Hepatotoxicity
💫 #MetALD affects women differently. From greater alcohol sensitivity to menopause-related risk and transplant disparities, this review synthesizes evidence on sex-specific biology, outcomes, and care gaps in women with MetALD.
🔗: https://ow.ly/3OKR50ZTbQL
🔗: https://ow.ly/3OKR50ZTbQL
September 30, 2026 at 6:01 PM
💫 #MetALD affects women differently. From greater alcohol sensitivity to menopause-related risk and transplant disparities, this review synthesizes evidence on sex-specific biology, outcomes, and care gaps in women with MetALD.
🔗: https://ow.ly/3OKR50ZTbQL
🔗: https://ow.ly/3OKR50ZTbQL
AGA advises against bariatric surgery for MetALD patients.
AGA advises against bariatric surgery for MetALD patients
AGA advises against bariatric surgery for MetALD patients. The American Gastroenterological Association advises that endobariatric and bariatric surgery are not advisable for patients with metabolic dysfunction- and alcohol-associated liver disease (MetALD). This recommendation stems from a lack of safety and efficacy data and concerns that continued alcohol use after surgery could accelerate liver disease progression. Guideline, Clinical gastroenterology and hepatology, 22 Sep 2026.
enclai.net
September 27, 2026 at 11:00 AM
AGA advises against bariatric surgery for MetALD patients.
⭐ MASLD, MetALD and ALD are not static labels
📚 Prof Frank Tacke and team at Charité–Universitätsmedizin Berlin, Germany highlight dynamic transitions across SLD subtypes & call for longitudinal reassessment, objective alcohol measurement and trajectory-based management.
🔗 doi.org/10.1136/egas...
📚 Prof Frank Tacke and team at Charité–Universitätsmedizin Berlin, Germany highlight dynamic transitions across SLD subtypes & call for longitudinal reassessment, objective alcohol measurement and trajectory-based management.
🔗 doi.org/10.1136/egas...
September 22, 2026 at 8:32 AM
⭐ MASLD, MetALD and ALD are not static labels
📚 Prof Frank Tacke and team at Charité–Universitätsmedizin Berlin, Germany highlight dynamic transitions across SLD subtypes & call for longitudinal reassessment, objective alcohol measurement and trajectory-based management.
🔗 doi.org/10.1136/egas...
📚 Prof Frank Tacke and team at Charité–Universitätsmedizin Berlin, Germany highlight dynamic transitions across SLD subtypes & call for longitudinal reassessment, objective alcohol measurement and trajectory-based management.
🔗 doi.org/10.1136/egas...
A study from Mazen Noureddin, MD, (of @houstonmethodistmd.bsky.social), found that 11% of patients screened for #MASLD clinical trials had PEth results of ≥20 ng/mL, indicating a potential need for further clinical evaluation for possible #MetALD or #ALD.
www.docwirenews.com/post/phospha...
www.docwirenews.com/post/phospha...
Using Phosphatidylethanol to Rule Out MetALD/ALD | Docwire News
Among patients screened for MASLD clinical trials, 11% had PEth results that could indicate the potential for MetALD or ALD.
www.docwirenews.com
September 11, 2026 at 10:32 PM
A study from Mazen Noureddin, MD, (of @houstonmethodistmd.bsky.social), found that 11% of patients screened for #MASLD clinical trials had PEth results of ≥20 ng/mL, indicating a potential need for further clinical evaluation for possible #MetALD or #ALD.
www.docwirenews.com/post/phospha...
www.docwirenews.com/post/phospha...
in the metald gear straight up jorkin it
August 26, 2026 at 10:05 AM
in the metald gear straight up jorkin it
ICYMI: New online! Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications
Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications
Nature Reviews Gastroenterology & Hepatology, Published online: 18 August 2026; doi:10.1038/s41575-026-01240-6In this Review, Loomba and colleagues describe the global epidemiology, risk factors, natural history and clinical implications of metabolic and alcohol-associated liver disease (MetALD).
dlvr.it
August 24, 2026 at 1:11 PM
ICYMI: New online! Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications
ICYMI: New online! Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications
Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications
Nature Reviews Gastroenterology & Hepatology, Published online: 18 August 2026; doi:10.1038/s41575-026-01240-6In this Review, Loomba and colleagues describe the global epidemiology, risk factors, natural history and clinical implications of metabolic and alcohol-associated liver disease (MetALD).
dlvr.it
August 19, 2026 at 1:10 PM
ICYMI: New online! Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications
New online! Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications
Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications
Nature Reviews Gastroenterology & Hepatology, Published online: 18 August 2026; doi:10.1038/s41575-026-01240-6In this Review, Loomba and colleagues describe the global epidemiology, risk factors, natural history and clinical implications of metabolic and alcohol-associated liver disease (MetALD).
dlvr.it
August 18, 2026 at 1:09 PM
New online! Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications
📢 New Editorial in #eGastroenterology
🔄 Dr Lanlan Chen, Dr Paul Horn and Prof. Frank Tacke frame #MASLD–#MetALD–#ALD as a dynamic continuum, calling for longitudinal reassessment and objective alcohol measurement.
🔗 doi.org/10.1136/egastro-2026-100430
🔄 Dr Lanlan Chen, Dr Paul Horn and Prof. Frank Tacke frame #MASLD–#MetALD–#ALD as a dynamic continuum, calling for longitudinal reassessment and objective alcohol measurement.
🔗 doi.org/10.1136/egastro-2026-100430
August 10, 2026 at 8:43 AM
📢 New Editorial in #eGastroenterology
🔄 Dr Lanlan Chen, Dr Paul Horn and Prof. Frank Tacke frame #MASLD–#MetALD–#ALD as a dynamic continuum, calling for longitudinal reassessment and objective alcohol measurement.
🔗 doi.org/10.1136/egastro-2026-100430
🔄 Dr Lanlan Chen, Dr Paul Horn and Prof. Frank Tacke frame #MASLD–#MetALD–#ALD as a dynamic continuum, calling for longitudinal reassessment and objective alcohol measurement.
🔗 doi.org/10.1136/egastro-2026-100430
Fatty Liver= #SLD
#NAFLD= #MASLDf="/hashtag/MASLD" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MASLD
#NASH=#MASH
#MASLD who drink ethanol > 140 g F or 210 g M weekly= #MetALD
Alcohol related liver disease= #ALD
SLD with known cause (drug, Wilson, other genetic etc…) = specific etiology SLD
SLD without known metabolic or other risk= cryptogenic SL
#NAFLD= #MASLDf="/hashtag/MASLD" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MASLD
#NASH=#MASH
#MASLD who drink ethanol > 140 g F or 210 g M weekly= #MetALD
Alcohol related liver disease= #ALD
SLD with known cause (drug, Wilson, other genetic etc…) = specific etiology SLD
SLD without known metabolic or other risk= cryptogenic SL
December 2, 2024 at 8:02 PM
Fatty Liver= #SLD
#NAFLD= #MASLDf="/hashtag/MASLD" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MASLD
#NASH=#MASH
#MASLD who drink ethanol > 140 g F or 210 g M weekly= #MetALD
Alcohol related liver disease= #ALD
SLD with known cause (drug, Wilson, other genetic etc…) = specific etiology SLD
SLD without known metabolic or other risk= cryptogenic SL
#NAFLD= #MASLDf="/hashtag/MASLD" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MASLD
#NASH=#MASH
#MASLD who drink ethanol > 140 g F or 210 g M weekly= #MetALD
Alcohol related liver disease= #ALD
SLD with known cause (drug, Wilson, other genetic etc…) = specific etiology SLD
SLD without known metabolic or other risk= cryptogenic SL
I think the concept of MetALD Is very useful and should perhaps be expanded.
Today I saw a patient with MetHBV and another one with MetPBC #MASLD #MASH #fattyliver #NASH #gitwitter #LiverTwitter @AASLDtweets @EASLnews @marurinella @DrLoomba @AutoImmuneLiver
Today I saw a patient with MetHBV and another one with MetPBC #MASLD #MASH #fattyliver #NASH #gitwitter #LiverTwitter @AASLDtweets @EASLnews @marurinella @DrLoomba @AutoImmuneLiver
December 2, 2024 at 7:52 PM
I think the concept of MetALD Is very useful and should perhaps be expanded.
Today I saw a patient with MetHBV and another one with MetPBC #MASLD #MASH #fattyliver #NASH #gitwitter #LiverTwitter @AASLDtweets @EASLnews @marurinella @DrLoomba @AutoImmuneLiver
Today I saw a patient with MetHBV and another one with MetPBC #MASLD #MASH #fattyliver #NASH #gitwitter #LiverTwitter @AASLDtweets @EASLnews @marurinella @DrLoomba @AutoImmuneLiver
@HannesHagstrom presents data suggesting you should just swap existing ICD codes for #NAFLD to #MASLD and #NASH to #MASH and create a new category for #MetALD
People will widely adopt when they can bill appropriately so this is important to address ASAP. @AASLDtweets #TLM23
People will widely adopt when they can bill appropriately so this is important to address ASAP. @AASLDtweets #TLM23
December 2, 2024 at 6:49 PM
I was lukewarm to the name change but not to this…
🥯🍷MetALD
Once you start categorizing:
📍more fibrosis at presentation
📍more symptomatic
📍more serious comorbidities ep: ❤️ and TG
Need more studies
@rabataller @DrLoomba @juanpabloarab @AlkhouriNaim
#livertwitter
🥯🍷MetALD
Once you start categorizing:
📍more fibrosis at presentation
📍more symptomatic
📍more serious comorbidities ep: ❤️ and TG
Need more studies
@rabataller @DrLoomba @juanpabloarab @AlkhouriNaim
#livertwitter
December 2, 2024 at 5:16 PM
I was lukewarm to the name change but not to this…
🥯🍷MetALD
Once you start categorizing:
📍more fibrosis at presentation
📍more symptomatic
📍more serious comorbidities ep: ❤️ and TG
Need more studies
@rabataller @DrLoomba @juanpabloarab @AlkhouriNaim
#livertwitter
🥯🍷MetALD
Once you start categorizing:
📍more fibrosis at presentation
📍more symptomatic
📍more serious comorbidities ep: ❤️ and TG
Need more studies
@rabataller @DrLoomba @juanpabloarab @AlkhouriNaim
#livertwitter
#livertwitter would you consider using #rezdiffra in a person with F3 & strong metabolic risk factors who also meets definition of 🍷🥯 MetALD?
December 2, 2024 at 5:16 PM
#livertwitter would you consider using #rezdiffra in a person with F3 & strong metabolic risk factors who also meets definition of 🍷🥯 MetALD?
With the advent of pETH that I check on every single new patient, I would say that easily 20% of those I used to diagnose with #MASH have MetALD 🍷🥯
Clinical trials for these patients are desperately needed #livertwitter
Clinical trials for these patients are desperately needed #livertwitter
December 2, 2024 at 5:11 PM
With the advent of pETH that I check on every single new patient, I would say that easily 20% of those I used to diagnose with #MASH have MetALD 🍷🥯
Clinical trials for these patients are desperately needed #livertwitter
Clinical trials for these patients are desperately needed #livertwitter
In today’s #readoftheweek📚, discover how targeting DHCR7 can become a strategy for the treatment of #MetALD and #HCC.
Read this JHEP Reports article: www.jhep-reports.eu/article/S258...
@ucsandiego.bsky.social #LiverSky
Read this JHEP Reports article: www.jhep-reports.eu/article/S258...
@ucsandiego.bsky.social #LiverSky
June 19, 2025 at 11:53 AM
In today’s #readoftheweek📚, discover how targeting DHCR7 can become a strategy for the treatment of #MetALD and #HCC.
Read this JHEP Reports article: www.jhep-reports.eu/article/S258...
@ucsandiego.bsky.social #LiverSky
Read this JHEP Reports article: www.jhep-reports.eu/article/S258...
@ucsandiego.bsky.social #LiverSky
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
Register now: bit.ly/3Jmukor. #HepSky #MedSky
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
Register now: bit.ly/3Jmukor. #HepSky #MedSky
November 8, 2025 at 5:30 PM
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
Register now: bit.ly/3Jmukor. #HepSky #MedSky
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
Register now: bit.ly/3Jmukor. #HepSky #MedSky
In @aga-cgh.bsky.social: Lean vs nonlean MetALD is independently associated with a 28% higher risk for major adverse liver outcomes and an 82% higher risk for all-cause mortality.
https://www.gastroenterologyadvisor.com/news/lean-metald-clinical-features-resemble-alcohol-associated-liver-disease/
https://www.gastroenterologyadvisor.com/news/lean-metald-clinical-features-resemble-alcohol-associated-liver-disease/
Lean MetALD Clinical Features Resemble Alcohol-Associated Liver Disease
Patients with lean vs nonlean MetALD have significantly higher risks for major adverse liver outcomes and all-cause mortality.
www.gastroenterologyadvisor.com
July 13, 2026 at 11:52 PM
In @aga-cgh.bsky.social: Lean vs nonlean MetALD is independently associated with a 28% higher risk for major adverse liver outcomes and an 82% higher risk for all-cause mortality.
https://www.gastroenterologyadvisor.com/news/lean-metald-clinical-features-resemble-alcohol-associated-liver-disease/
https://www.gastroenterologyadvisor.com/news/lean-metald-clinical-features-resemble-alcohol-associated-liver-disease/